Selective inhibitor of neuronal nitric oxide synthase (nNOS; NOS I) relative to inducible nitric oxide synthase (iNOS; NOS II) (115-fold) and endothelial nitric oxide synthase (eNOS; NOS III) (29-fold).
Product Details
| Alternative Name: | ETPI . HCl, TFPI . HCl, SEPIT . HCl, ETU |
| |
| Formula: | C10H11SN2F3 . HCl |
| |
| MW: | 248.3 . 36.5 |
| |
| CAS: | 163490-78-6 |
| |
| Purity: | ≥98% |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in water (50mg/ml), methanol, 100% ethanol (33mg/ml), DMSO (33mg/ml) or dimethyl formamide (33mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase: T. Castano, et al.; Bioorg. Med. Chem.
16, 6193 (2008),
Abstract;
Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS: S. Philipp, et al.; Am. J. Physiol. Heart Circ. Physiol.
290, H450 (2006),
Abstract;
Full Text
Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2: Y. Wang, et al.; Circ. Res.
95, 84 (2004),
Abstract;
Full Text
Cellular and enzymatic studies of N(omega)-propyl-l-arginine and S-ethyl-N-[4-(trifluoromethyl)phenyl]isothiourea as reversible, slowly dissociating inhibitors selective for the neuronal nitric oxide synthase isoform: G.R. Cooper, et al.; Arch. Biochem. Biophys.
375, 183 (2000),
Abstract;
Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivity: B.G. Shearer, et al.; J. Med. Chem.
40, 1901 (1997),
Abstract;
